Therapies less invasive than surgery and more effective than lifestyle and pharmacotherapy are needed to contend with the obesity epidemic.
Intragastric balloons are a minimally invasive endoscopic weight loss method recently approved for use in the US.
Dr Violeta Popov and colleagues from New York, USA assessed the effect of intragastric balloons on metabolic outcomes associated with obesity.
The team searched MEDLINE, Embase, and Cochrane Database through 2016.
Dual extraction and quality assessment of studies using Cochrane risk of bias tool were performed independently by 2 authors.
The research team's primary outcomes included the change from baseline in metabolic parameters.
|The rate of serious adverse events was about 1%|
|American Journal of Gastroenterology|
Secondary outcomes included resolution and/or improvement in metabolic co-morbidities and association with baseline parameters.
The researchers identified 10 randomized controlled trials, and 30 observational studies including 5,668 subjects were analyzed.
There was moderate-quality evidence for improvement in most metabolic parameters in subjects assigned to intragastric balloons therapy as compared to conventional non-surgical therapy in randomized controlled trials.
The team found that the mean difference in fasting glucose change was −12.7 mg/dl, −19 mg/dl in triglycerides, −4.1 cm in waist circumference, −2.9 mm Hg in diastolic blood pressure.
The odds ratio for diabetes resolution after intragastric balloon therapy was 1.4.
The researchers found that the rate of serious adverse events was about 1%.
Dr Popov's team concludes, "Intragastric balloons are more effective than diet in improving obesity-related metabolic risk factors with a low rate of adverse effects, however the strength of the evidence is limited given the small number of participants and lack of long-term follow-up."